ARCT · Arcturus Therapeutics Holdings Inc.

Track ARCT — free

$14.66 +1.63 (+12.51%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$389.82M

28.42M

Volume · Oct 5 1.32M Avg daily vol (3M) 926.07K

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q1 2026 earnings call transcript

call held May 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-40.4%

Trailing year

Short interest

19.2%

Latest settlement · 6.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +72%

above

Price vs 50-day avg +23%

above

RSI (14) 55

neutral

MACD trend Negative

52-week position 52%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −7%

trailing

6-month return +69%

trailing

YTD return +139%

this year

Relative strength +57%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $12 › 200d $9 — 50d above 200d

Institutional flow Accumulating

1 of 136 funds reported for Sep 30 · net +2.6K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

19.24% of float · ▼ -10.3% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

136 holders — mid 3-yr range

Squeeze score 72

high risk · 0–100

Fundamentals

Fair

Revenue growth −46%

Y/Y

EPS growth +20%

Y/Y

Free cash flow $-74.5M

Balance sheet $355.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 91%

annualized · 1-yr

Max drawdown −76%

past year

ATR 8.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+72% Bullish

Price vs 50-day avg

+23% Bullish

RSI (14)

55 Neutral

MACD trend

Negative Bearish

52-week position

52% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $12 › 200d $9 — 50d above 200d

Institutional flow Accumulating

1 of 136 funds reported for Sep 30 · net +2.6K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

19.24% of float · ▼ -10.3% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

136 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $6 Now $15 · 52% Range high $23

vs 200-day avg +72% vs 50-day avg +23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARCT Arcturus Therapeutics Holdings Inc. this stock	$389.82M	+139.2%	-46.1%	—	19.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

136

% held: 88.0%
Reported: 1 of 136
Top holder: FEDERATED HERMES, INC.

Held Float

View

Held by Funds

Fund positions

152

View

Short & Settlement

Short Interest Falling

Shares short

5.5M

Days to cover: 6.4d
Change: -628.9K sh

View

Short Volume

Short vol %

35%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

262

Value: $3.7K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

43.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$82.0M

Net income (FY): $-65.8M
EPS diluted: $-2.40

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 23, 2026
This year: 13

View

Proposed Sales

Value

$249.1K

Shares: 12.0K
Filed: Oct 15, 2024

View

Earnings & Events

Webcasts

Last webcast

Sep 23, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ARCT	+1.4%	-7.3%	+68.9%	+7.1%	+139.2%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	+0.2%	-7.9%	+57.3%	+5.5%	+125.5%

Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 7 filings 3 filers Visit website Investor relations

ARCT · Arcturus Therapeutics Holdings Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance